Drug intelligence / Profile preview

EVT070

Development stage: Unknown
Lead developer: Evotec

Overview

EVT070 was a drug candidate that was under development by Evotec and Boehringer Ingelheim. In October 2014, Boehringer Ingelheim decided to discontinue its development for strategic reasons, and the rights to the project reverted back to Evotec. The specific mechanism of action, modality, and primary indication for which EVT070 was being developed are not publicly disclosed in the provided context.

Beyond the preview

Go deeper on EVT070.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVT070.

Explore the full profile